DOSSIER · 13F Holders · Q1 2026Healthcare · In Vitro & In Vivo Diagnostic Substances
NTLA
INTELLIA THERAPEUTICS INC
329 institutions still hold INTELLIA THERAPEUTICS INC as of Q1 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
CUSIP 45826J105·In Vitro & In Vivo Diagnostic Substances·329 13F holders·last filed Mar 31, 2026
AI Holders Summary · Q1 2026
Intellia Therapeutics' Q2 2026 tracked ownership is a two-holder snapshot: Versant Capital Management owns about .5K, roughly 88% of the reported value, and MassMutual Private Wealth & Trust owns about .7K, roughly 12%. The key read is that both holders reduced share count—Versant from 2,095 to 1,626 and MassMutual from 231 to 219—even though reported values rose, so NTLA's visible ownership became smaller in exposure while remaining concentrated in Versant.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.
Page 1 of 17
309 more holders available. Log in →